Rhythm Pharmaceuticals Inc. (RYTM)
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript
Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision
Rhythm Pharmaceuticals delivered strong FY25 revenue growth, driven by global demand for IMCIVREE (setmelanotide), reaching $194.8 million, up 50% year-over-year. RYTM's upcoming March 20th FDA PDUFA decision for setmelanotide in acquired hypothalamic obesity could expand the addressable market to 25,000–28,000 patients globally. Positive Phase 3 TRANSCEND data showed a -16.4% mean BMI reduction for setmelanotide, supporting its potential as the first targeted therapy for acquired hypothalamic obesity.
Cinctive Capital Management LP Sells 35,781 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
Cinctive Capital Management LP decreased its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 50.4% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 35,156 shares of the company's stock after selling 35,781 shares during the quarter. Cinctive Capital Management LP owned
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.72 per share a year ago.
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy?
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. ( RYTM ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants David Connolly - Head of Investor Relations & Corporate Communications David Meeker - Chairman, President & CEO Jennifer Chien - Executive VP & Head of North America Yann Mazabraud - Executive VP & Head of International Hunter Smith - CFO & Treasurer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Philip Nadeau - TD Cowen, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Angela Qian Faisal Khurshid - Leerink Partners LLC, Research Division Erik Wong Julian Pino Evan Wang Georgia Ban Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Presentation Operator " David Connolly Head of Investor Relations & Corporate Communications " David Meeker Chairman, President & CEO " Jennifer Chien Executive VP & Head of North America " Yann Mazabraud Executive VP & Head of International " Hunter Smith CFO & Treasurer " Michael Ulz Morgan Stanley, Research Division " Morgan Stanley, Research Division Philip Nadeau TD Cowen, Research Division " TD Cowen, Research Division Derek Archila Wells Fargo Securities, LLC, Research Division " Wells Fargo Securities, LLC, Research Division Angela Qian " Canaccord Genuity, Research Division Faisal Khurshid Leerink Partners LLC, Research Division " Leerink Partners LLC, Research Division Erik Wong " Goldman Sachs, Research Division Julian Pino " Stifel, Nicolaus & Company, Incorporated, Research Division Evan Wang " Guggenheim Securities, LLC, Research Division Georgia Ban " Jefferies LLC, Research Division Raghuram Selvaraju H.C.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.73 per share a year ago.
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David P. Meeker - Chairman, President & CEO Hunter C.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.55 per share a year ago.
